Table 2: Time to Hospitalisation, Pulmonary Status and Therapeutics Prior to the Initiation of ECMO.
| Time from symptom onset to hospitalisation | 5.0 ± 2.3 days |
| Time from symptom onset to intubation | 6.9 ± 2.5 days |
| Time from intubation to ECMO initiation | 3.7 ± 2.7 days |
| PEEP at time of ECMO | 16.8 ± 3.0 mmHg |
| PaO2/FiO2 ratio at time of ECMO | 88.6 ± 33.0 |
| LVEF at time of ECMO | 55 ± 9.1% |
| Incidence of RV dysfunction at time of ECMO | 14.2% (1/7) |
| Therapeutics prior to ECMO | |
| Inhaled epoprostenol | 100% |
| Mechanical proning | 100% |
| Paralytics | 100% |
| Steroids (hydrocortisone or methylprednisolone) | 100% |
| Azithromycin | 100% |
| Hydroxychloroquine | 85.7% (6/7) |
| Tocilizumab (compassionate use) | 14.2% (1/7) |
| ACCT trial enrolment | 14.2% (1/7) |
| COVACTA trial enrolment | 14.2% (1/7) |
| Convalescent plasma | 57.1% (4/7) |
| IV immunoglobulin | 14.2% (1/7) |
ECMO = extracorporeal membrane oxygenation; LVEF= left ventricular ejection fraction; RV = right ventricle.